Motif Bio Files Registration Statement for Proposed U.S. Public Offering of American Depositary Shares and Applies for NASDAQ Listing

LONDON, UNITED KINGDOM--(Marketwired - Jul 13, 2016) - Motif Bio plc (AIM: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, announces that it has filed a registration statement on Form F-1 with the U.S. Securities and Exchange Commission ("SEC") relating to a proposed public offering of American Depositary Shares ("ADSs"). Motif Bio has also applied to have its ADSs listed on the NASDAQ Global Select Market under the ticker symbol "MTFB". Following completion of the offering of the ADSs, Motif Bio's ordinary shares will continue to trade on the AIM market of the London Stock Exchange. The number of ADSs to be offered and the price per ADS for the offering have not yet been determined.

SunTrust Robinson Humphrey, Inc. is acting as the book-running manager for the offering.

A registration statement relating to these securities has been filed with the SEC, but has not yet become effective. These securities may not be sold, nor may offers to buy these securities be accepted, prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or a solicitation of an offer to buy any securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

The offering will be made only by means of a prospectus. When available, copies of the preliminary prospectus relating to the offering may be obtained from SunTrust Robinson Humphrey, 3333 Peachtree Road NE, 9th Floor, Atlanta, GA 30326, Attention: Prospectus Department; Email:; Telephone: 404-926-5744; or fax: 404-926-5464.

About Motif Bio

Motif Bio is a clinical-stage biopharmaceutical company, engaged in the research and development of novel antibiotics designed to be effective against serious and life-threatening infections in hospitalized patients caused by multi-drug resistant bacteria. Our lead product candidate, iclaprim, is being developed for the treatment of acute bacterial skin and skin structure infections (ABSSSI) and hospital acquired bacterial pneumonia (HABP), including ventilator associated bacterial pneumonia (VABP), which is often caused by MRSA (methicillin resistant Staphylococcus aureus). We are currently enrolling and dosing patients in two global Phase 3 clinical trials with an intravenous formulation of iclaprim, for the treatment of ABSSSI, which are expected to complete in the second half of 2017.

Contact Information:

For further information please contact:

Motif Bio plc
Richard Morgan
Graham Lumsden
Chief Executive Officer

Zeus Capital Limited (NOMAD & BROKER)
Phil Walker/Giles Balleny
Dominic Wilson
+44 (0)20 3829 5000

Northland Capital Partners Limited (BROKER)
Patrick Claridge/David Hignell
John Howes/Rob Rees (Broking)
+44 (0)20 3861 6625

Walbrook PR Ltd. (FINANCIAL PR & IR)
+44 (0)20 7933 8780

Paul McManus
Mob: +44 (0)7980 541 893

Mike Wort
Mob: +44 (0)7900 608 002

Raimund Gabriel
+49 (0)89 210 2280